OMER - Omeros Corporation
| Previous Close | 18.93 |
| Open | 18.91 |
| Bid | 18.18 x 800 |
| Ask | 19.55 x 1000 |
| Day's Range | 18.42 - 19.06 |
| 52 Week Range | 10.30 - 27.00 |
| Volume | 338,789 |
| Avg. Volume | 608,967 |
| Market Cap | 907.697M |
| Beta (3Y Monthly) | 3.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.61 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.75 |
- Business Wire•18 days ago
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
Omeros Corporation (OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) following narsoplimab treatment under a compassionate-use protocol. The case was presented at the 2019 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) held March 24-27 in Frankfurt, Germany. Omeros is reporting the case to ensure broad availability of the information presented.
- Business Wire•last month
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
Omeros Corporation (OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Omeros, the educational session entitled “How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at 2:00-3:30 PM local time. There is growing recognition that hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a potentially lethal complication of stem-cell transplants, is underdiagnosed in the U.S. and worldwide.
- Zacks•last month
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of OMER earnings conference call or presentation 1-Mar-19 1:30pm GMT
Q4 2018 Omeros Corp Earnings Call
- Business Wire•2 months ago
Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
– Conference Call Today at 8:30 a.m. ET –
- Business Wire•2 months ago
Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
Omeros Corporation (OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
- GlobeNewswire•2 months ago
Investor Expectations to Drive Momentum within Graphic Packaging Holding, Vulcan Materials, Omeros, Koppers, uniQure N.V, and WAVE Life Sciences — Discovering Underlying Factors of Influence
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Business Wire•2 months ago
Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
Omeros Corporation today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.” Narsoplimab is the company’s lead human monoclonal antibody targeting mannan-binding ...
- Motley Fool•2 months ago
Why Omeros Stock Jumped Today
The small biotech received good news from the FDA.
- Business Wire•2 months ago
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
Omeros Corporation (OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the required work and further advanced its preparations for its Biologics License Application (BLA) for OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is the company’s Phase 3 human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
- Business Wire•2 months ago
Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
Omeros Corporation (OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company.
- Simply Wall St.•3 months ago
Can We See Significant Insider Ownership On The Omeros Corporation (NASDAQ:OMER) Share Register?
A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
- Benzinga•3 months ago
Omeros Finalizes Clinical Plan For Kidney Disease Treatment, Reports Additional Positive Phase 2 Data
IgA nephropathy is a kidney disease resulting from the accumulation of an antibody called immunoglobin A in the kidney, which causes inflammation and in turn impacts the ability of the kidney to filter wastes from blood. Following a meeting with the FDA on the Phase 3 trial, Omeros said Thursday it has finalized its clinical plan for OMS721. The company said the FDA agreed to extend the primary endpoint of the assessment of proteinuria from 24 weeks to 36 weeks to allow additional dosing if warranted.
- Business Wire•3 months ago
Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
Omeros Corporation (OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. There is no approved treatment for IgA nephropathy.
- Business Wire•3 months ago
Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
Omeros Corporation (OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018. Omeros’ preliminary (unaudited) total and OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% revenues for the fourth quarter of 2018 are expected to be a record high at approximately $22.0 million compared to $4.6 million in 3Q 2018 and $13.8 million in the prior year fourth quarter. The increase from the prior periods reflects strong demand for OMIDRIA from ambulatory surgery centers (ASCs) and hospitals following reinstatement of pass-through reimbursement for OMIDRIA on October 1, 2018.
- GlobeNewswire•4 months ago
Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics — Discovering Underlying Factors of Influence
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Business Wire•4 months ago
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
Omeros Corporation (OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy. The committee includes renowned leaders in nephrology and clinical research who will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
- Business Wire•4 months ago
Omeros Announces Research Collaboration with University of Cambridge
Omeros Corporation (OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.
- Business Wire•4 months ago
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –
- Business Wire•5 months ago
Omeros Announces Additions to Senior Management Team
Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Omeros Corp Earnings Call
- GlobeNewswire•5 months ago
New Research Coverage Highlights Omeros, Apple, Bio-Rad Laboratories, Cott, Darling Ingredients, and Osisko Gold Royalties — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Simply Wall St.•5 months ago
Does Omeros Corporation’s (NASDAQ:OMER) CEO Salary Reflect Performance?
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
- Motley Fool•5 months ago
Here's Why Omeros Corporation Fell as Much as 24.5% Today
The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.
- Benzinga•5 months ago
The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...
